Compare VMC & RMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VMC | RMD |
|---|---|---|
| Founded | 1909 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Mining & Quarrying of Nonmetallic Minerals (No Fuels) | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.0B | 36.4B |
| IPO Year | N/A | 1995 |
| Metric | VMC | RMD |
|---|---|---|
| Price | $296.60 | $250.60 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 13 | 13 |
| Target Price | ★ $314.38 | $292.27 |
| AVG Volume (30 Days) | ★ 911.3K | 893.0K |
| Earning Date | 10-30-2025 | 01-29-2026 |
| Dividend Yield | 0.66% | ★ 0.95% |
| EPS Growth | ★ 32.66 | 29.59 |
| EPS | 8.42 | ★ 9.77 |
| Revenue | ★ $7,882,200,000.00 | $5,257,400,000.00 |
| Revenue This Year | $8.89 | $9.85 |
| Revenue Next Year | $4.95 | $7.32 |
| P/E Ratio | $34.94 | ★ $25.82 |
| Revenue Growth | 6.54 | ★ 9.36 |
| 52 Week Low | $215.08 | $199.92 |
| 52 Week High | $311.74 | $293.81 |
| Indicator | VMC | RMD |
|---|---|---|
| Relative Strength Index (RSI) | 55.00 | 48.59 |
| Support Level | $289.57 | $245.97 |
| Resistance Level | $303.75 | $259.99 |
| Average True Range (ATR) | 5.48 | 5.40 |
| MACD | 0.90 | 0.59 |
| Stochastic Oscillator | 60.69 | 62.13 |
Vulcan Materials is the United States' largest producer of construction aggregates (crushed stone, sand, and gravel). Its largest markets include Texas, California, Virginia, Tennessee, Georgia, Florida, North Carolina, and Alabama. In 2024, Vulcan sold 219.9 million tons of aggregates, 13.6 million tons of asphalt mix, and 3.6 million cubic yards of ready-mix. As of Dec. 31, 2024, the company had 16.5 billion tons of aggregate reserves.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.